Mydecine Innovations Group Signs Definitive Agreement To Acquire Mindleap Health’s Advanced Digital Telehealth Platform

Mydecine Innovations Group Inc. (Mydecine) announced that it has signed a definitive share exchange agreement with Mindleap Health Inc. (Mindleap) for the acquisition of a 100% interest in MindLeap's Digital Telehealth Platform focused on the emerging psychedelics industry. Mydecine will acquire 100% of the issued and outstanding shares of Mindleap in exchange for: (i) 6,363,636 common shares in the capital of the Company, and (ii) the binding commitment to advance CAD $500,000 in working capital to Mindleap upon closing of the transaction and an additional CAD $500,000 on or before September 1, 2020.

Certain principals . . .